Cosimo Lobello

This paper identifies VCB1, a novel ACLY inhibitor, which overcomes TKI resistance in lymphoma by disrupting lipid and nucleotide metabolism, ISR, and redox homeostasis.

This study identifies tyrosine phosphorylation and dimerization as cooperative mechanisms activating NAMPT, enhancing NAD+ synthesis and cancer cell growth.

This paper identifies ACSS1 as a metabolic driver in lymphomas, showing its role in acetate-to-acetyl-CoA conversion and pyrimidine biosynthesis, and demonstrates that targeting ACSS1 suppresses tumor growth.